Items where Author is "Amato, M. P."

(2025) First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Neurotherapeutics. p. 12. ISSN 1933-7213

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. Multiple Sclerosis Journal-Experimental Translational and Clinical. p. 13.

(2024) Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation. ISSN 23327812 (ISSN)

(2024) Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies. Journal of Neurology. pp. 472-485. ISSN 1432-1459 (Electronic) 0340-5354 (Print) 0340-5354 (Linking)

(2024) A standardised definition of progression independent of relapse activity in multiple sclerosis. Multiple Sclerosis Journal. pp. 442-445. ISSN 1352-4585

(2023) Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 707-717. ISSN 0022-3050

(2023) Effect of high-efficacy therapy on the course of disability in paediatric-onset multiple sclerosis. Multiple Sclerosis Journal. pp. 103-105. ISSN 1352-4585

(2023) A Multi-Country Comparative Effectiveness Study of Dimethyl Fumarate and Non-Specific Immunosuppressants in a Real-World Setting: Evidence from MSBase. Multiple Sclerosis Journal. NP29-NP30. ISSN 1352-4585

(2023) Vascular comorbidities are associated with increased relapse rates in relapsing-remitting MS. Multiple Sclerosis Journal. pp. 84-86. ISSN 1352-4585

(2022) Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. NEUROLOGY. ISSN 0028-3878

(2022) Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 947-950. ISSN 1352-4585

(2022) The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Journal. pp. 967-970. ISSN 1352-4585

(2019) Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. Jama-Journal of the American Medical Association. pp. 175-187. ISSN 0098-7484

(2018) Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple sclerosis (Houndmills, Basingstoke, England). pp. 642-652. ISSN 1477-0970 (Electronic) 1352-4585 (Linking)

(2017) Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal. pp. 266-276. ISSN 1352-4585

(2017) Prognostic Indicators in Pediatric Clinically Isolated Syndrome. Annals of Neurology. pp. 729-739. ISSN 0364-5134

(2017) Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. pp. 2426-2443. ISSN 0006-8950

(2016) Early disease modifying treatment delays disability accumulation in patients with pediatric onset clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal. pp. 62-63. ISSN 1352-4585

(2016) Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 1343-1349. ISSN 0022-3050

(2016) Individual response to disease modifying therapies: a global observational cohort study. Multiple Sclerosis Journal. pp. 358-360. ISSN 1352-4585

(2016) Long-term disability trajectories in primary progressivs MS patients - a latent class growth analysis. Multiple Sclerosis Journal. pp. 44-46. ISSN 1352-4585

(2015) Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. Plos One. ISSN 1932-6203